ELAN Quote, Financials, Valuation and Earnings

Axogen has a net margin of -0.78% compared to Elanco Animal Health's net margin of 0.91%. Elanco Animal Health's return on equity of 5.48% beat Axogen's return on equity of -10.21%.

Elanco Animal Health has a consensus price target of $15.42, signalling upside risk potential of 47.67%. On the other hand Axogen has an analysts' consensus of $25.00 which suggests that it could grow by 44.76%. Given that Elanco Animal Health has higher upside potential than Axogen, analysts believe Elanco Animal Health is more attractive than Axogen.

Elanco Animal Health has a beta of 1.439, which suggesting that the stock is 43.861% more volatile than S&P 500. In comparison Axogen has a beta of 1.024, suggesting its more volatile than the S&P 500 by 2.388%.

Elanco Animal Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elanco Animal Health pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.

Elanco Animal Health quarterly revenues are $1B, which are larger than Axogen quarterly revenues of $49.4M. Elanco Animal Health's net income of -$8M is lower than Axogen's net income of $450K. Notably, Elanco Animal Health's price-to-earnings ratio is 15.58x while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health is 1.17x versus 4.08x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.

Fulcrum Therapeutics has a net margin of -0.78% compared to Elanco Animal Health's net margin of 69.26%. Elanco Animal Health's return on equity of 5.48% beat Fulcrum Therapeutics's return on equity of -8.07%.

Elanco Animal Health has a consensus price target of $15.42, signalling upside risk potential of 47.67%. On the other hand Fulcrum Therapeutics has an analysts' consensus of $5.67 which suggests that it could grow by 81.62%. Given that Fulcrum Therapeutics has higher upside potential than Elanco Animal Health, analysts believe Fulcrum Therapeutics is more attractive than Elanco Animal Health.

Elanco Animal Health has a beta of 1.439, which suggesting that the stock is 43.861% more volatile than S&P 500. In comparison Fulcrum Therapeutics has a beta of 2.198, suggesting its more volatile than the S&P 500 by 119.83%.

Elanco Animal Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fulcrum Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elanco Animal Health pays -- of its earnings as a dividend. Fulcrum Therapeutics pays out -- of its earnings as a dividend.

Elanco Animal Health quarterly revenues are $1B, which are larger than Fulcrum Therapeutics quarterly revenues of $80M. Elanco Animal Health's net income of -$8M is higher than Fulcrum Therapeutics's net income of -$16.6M. Notably, Elanco Animal Health's price-to-earnings ratio is 15.58x while Fulcrum Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health is 1.17x versus -- for Fulcrum Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Integra Lifesciences Holdings has a net margin of -0.78% compared to Elanco Animal Health's net margin of 4.39%. Elanco Animal Health's return on equity of 5.48% beat Integra Lifesciences Holdings's return on equity of -0.45%.

Elanco Animal Health has a consensus price target of $15.42, signalling upside risk potential of 47.67%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $26.25 which suggests that it could grow by 17.45%. Given that Elanco Animal Health has higher upside potential than Integra Lifesciences Holdings, analysts believe Elanco Animal Health is more attractive than Integra Lifesciences Holdings.

Elanco Animal Health has a beta of 1.439, which suggesting that the stock is 43.861% more volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.861%.

Elanco Animal Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elanco Animal Health pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Elanco Animal Health quarterly revenues are $1B, which are larger than Integra Lifesciences Holdings quarterly revenues of $442.6M. Elanco Animal Health's net income of -$8M is lower than Integra Lifesciences Holdings's net income of $19.4M. Notably, Elanco Animal Health's price-to-earnings ratio is 15.58x while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health is 1.17x versus 1.07x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Orthofix Medical has a net margin of -0.78% compared to Elanco Animal Health's net margin of -13.52%. Elanco Animal Health's return on equity of 5.48% beat Orthofix Medical's return on equity of -22.96%.

Elanco Animal Health has a consensus price target of $15.42, signalling upside risk potential of 47.67%. On the other hand Orthofix Medical has an analysts' consensus of $24.30 which suggests that it could grow by 47.01%. Given that Elanco Animal Health has higher upside potential than Orthofix Medical, analysts believe Elanco Animal Health is more attractive than Orthofix Medical.

Elanco Animal Health has a beta of 1.439, which suggesting that the stock is 43.861% more volatile than S&P 500. In comparison Orthofix Medical has a beta of 1.058, suggesting its more volatile than the S&P 500 by 5.812%.

Elanco Animal Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orthofix Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elanco Animal Health pays -- of its earnings as a dividend. Orthofix Medical pays out -- of its earnings as a dividend.

Elanco Animal Health quarterly revenues are $1B, which are larger than Orthofix Medical quarterly revenues of $215.7M. Elanco Animal Health's net income of -$8M is higher than Orthofix Medical's net income of -$29.1M. Notably, Elanco Animal Health's price-to-earnings ratio is 15.58x while Orthofix Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health is 1.17x versus 0.79x for Orthofix Medical. Usually stocks with elevated PS ratios are considered overvalued.